- Home
- IMVT
IMVT
Immunovant Inc.
as 03-25-2025 12:34pm EST
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 3.4B | IPO Year: | N/A |
| Target Price: | $44.13 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.01 - $34.47 | Next Earning Date: | 02-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fromkin Andrew J. | IMVT | Director | Mar 7 '25 | Sell | $19.74 | 8,000 | $156,768.96 | 93,297 | |
| Macias William L. | IMVT | Chief Medical Officer | Feb 19 '25 | Sell | $20.86 | 2,055 | $42,867.30 | 357,353 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Feb 19 '25 | Sell | $20.86 | 2,814 | $58,700.04 | 321,952 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Feb 19 '25 | Sell | $20.86 | 15,439 | $322,057.54 | 948,786 | |
| Geffner Michael | IMVT | Chief Medical Officer | Jan 22 '25 | Sell | $23.59 | 2,657 | $62,678.63 | 132,314 | |
| Stout Jay S | IMVT | Chief Technology Officer | Jan 22 '25 | Sell | $23.59 | 2,195 | $51,780.05 | 139,991 | |
| Macias William L. | IMVT | Chief Medical Officer | Jan 15 '25 | Sell | $24.00 | 2,383 | $56,782.17 | 357,353 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Jan 15 '25 | Sell | $24.00 | 2,298 | $54,756.80 | 321,952 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Jan 15 '25 | Sell | $24.00 | 8,767 | $208,899.97 | 948,786 | |
| Roivant Sciences Ltd. | IMVT | Director10% Owner | Jan 13 '25 | Buy | $20.00 | 16,845,010 | $336,900,200.00 | 96,650,341 |
Latest Immunovant Inc. News
IMVT Breaking Stock News: Dive into IMVT Ticker-Specific Updates for Smart Investing
TipRanks
5 days ago
Immunovant price target raised to $61 from $58 at Stifel
TipRanks
6 days ago
Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright
Zacks
6 days ago
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Investor's Business Daily
7 days ago
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.
Clinical Trials Arena
7 days ago
Immunovant will not seek approval for MG therapy, despite hitting endpoints
Benzinga
7 days ago
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
Investor's Business Daily
7 days ago
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
MT Newswires
7 days ago
Immunovant Says Currently Not Planning to Seek Approval of Batoclimab for Myasthenia Gravis; Shares Drop Pre-Bell
Compare IMVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.